Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04 mars 2025 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress
27 févr. 2025 07h30 HE
|
Intellia Therapeutics, Inc.
Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
20 févr. 2025 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04 févr. 2025 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
22 janv. 2025 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
09 janv. 2025 16h00 HE
|
Intellia Therapeutics, Inc.
Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation Phase...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 janv. 2025 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03 déc. 2024 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
25 nov. 2024 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
16 nov. 2024 10h16 HE
|
Intellia Therapeutics, Inc.
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater...